Abstract 271P
Background
Immune checkpoint inhibitors are now considered revolutionary agents in the treatment of various cancers in the upfront and metastatic setting. The low toxicity and improved quality of life seen with these drugs are an added advantage. However, the real world data regarding their toxicities is limited. The currently published Indian data are restricted to isolated case reports. We planned this study of addressing toxicity profile of various Immunotherapy agents among Indian patients.
Methods
This prospective study was conducted at a tertiary care Hospital in Delhi from Aug 2019 till Nov 2021 after ethics approval. All patients included were treated with Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. All lines of therapy were allowed for enrolment. Immune Related adverse events were recorded for individual agents and therapy continued until progression or unacceptable toxicity. Toxicities were graded according to NCI:CTCAE criteria ver 4.0. Statistical analysis was done with the use of SPSS software ver 21.0.
Results
A total of 53 patients received Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. Majority of patients were less than 60 years of age (64.15%). ECOG PS was 1 in 66.04% and PS 2 in 32.08%. Carcinoma(Ca) Lung was the most frequent malignancy (n=18) followed by renal cell carcinoma (15.09%), Relapsed/Refractory Hodgkin’s Lymphoma ( 15.09%), Ca Urinary Bladder ( 11.32%), Malignant Melanoma (7.55%), Recurrent /Metastatic Head and neck cancer ( 7.55%), one each patient of Hepatocellular Ca, Ca Oesophagus, Stomach, Endometrium and Rectum.Nivolumab was used in the majority of study population (49.06%) followed by Pembrolizumab (37.74%), Atezolizumab (9.43%) and Durvalumab (3.77%). Majority of agents were used in 2nd line (52.83%) across various malignancies followed by 1st line usage in 22.64%, 3rd line in 11.32%, 4th line in 7.55% and 5th line usage in 5.66%. All grade adverse events were fatigue (73.58%), anaemia (62.26%), pneumonitis (16.98%), rash (11.32%), dyspnoea (9.43%), diarrhoea (9.43%) and hypothyroidism (7.55%) in majority of patients. Hyperglycaemia, pleural effusion, arthritis, arthralgia and infusion reaction comprising 1.89% each. Severe Grade 3 anaemia was seen in 1 patient (1.89%). None of these led to treatment discontinuation. Details of toxicities are depicted in the table. Table: 271P
Distribution of adverse events in total and in each drugs
Variables | Frequency | Percentage | Atezolizumab | Durvalumab | Nivolumab | Pembrolizumab | |
Dermatologic | Rash | 6 | 11.32% | 0 | 0 | 3 | 3 |
Grade (Gd) 1 | 4 | 7.55% | 0 | 0 | 2 | 2 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 | |
Gastroenterology | Diarrhoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 1 | 0 | |
Endocrine | Hyperglycaemia | 1 | 1.89% | 0 | 1 | 0 | 0 |
Gd 2 | 1 | 1.89% | 0 | 1 | 0 | 0 | |
Hypothyroidism | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 2 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Respiratory | Dyspnoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 5 | 9.43% | 1 | 0 | 2 | 2 | |
Pneumonitis | 9 | 16.98% | 0 | 0 | 4 | 5 | |
Gd 1 | 8 | 15.09% | 0 | 0 | 4 | 4 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Pleural effusion | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Hematologic | Anaemia | 33 | 62.26% | 3 | 1 | 17 | 12 |
Gd 1 | 31 | 58.49% | 3 | 1 | 17 | 10 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Infusion related | Gd 1 | 1 | 1.89% | 0 | 0 | 0 | 1 |
General | Fatigue | 39 | 73.58% | 5 | 1 | 17 | 16 |
Gd 1 | 37 | 69.81% | 5 | 1 | 16 | 15 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 |
Conclusions
Overall, the toxicity seen in Indian patients largely comparable with international experiences and Oncologists should feel reassured using these agents in similar settings in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
236P - Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 03
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis
Presenter: Hao-Wen Chuang
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03